• MULN received an order for one thousand class 3 trucks from its dealer partner, Randy Marion Automotive
• The company is excited about entering the next phase of its commercial launch with the Mullen THREE
• Mullen inked a $15 million vehicle purchase agreement with the MGT Lease Company for 250 class 3 cab chassis EV trucks

On the heels of several purchase agreements and orders, Mullen Automotive (NASDAQ: MULN) is experiencing impressive momentum as it continues to focus on growing in the electric vehicle space. Most recently, the company received a 1,000-unit purchase order (https://ibn.fm/2tLyU) and announced a $15.7 million vehicle purchase order with a lease company, both for its Mullen THREE class 3 truck (https://ibn.fm/y31v4).

The order for one thousand class 3 trucks came from Mullen’s dealer partner, Randy Marion Automotive, which earlier this month received the first class 3 demonstration vehicle for customer test drives and demonstrations. “Based on the tremendous interest we received on the Mullen class 3 truck, we placed our 1,000-vehicle order,” said Brad Sigmon, the fleet general manager and vice president of Randy Marion Automotive fleet operations. “We have a lineup of our customers waiting to pilot this truck including Duke Energy, Lowes and UNC-Charlotte.”

Mullen has announced that the class 3 truck will be priced at $68,500 and includes an estimated 130-mile range along with a 5,800-pound payload and capability of carrying a 14-foot box with more than 1,000 cubic feet of cargo capacity.

Mullen chief commercial officer John Schwegman noted that the company is excited about entering the next phase of its commercial launch with the Mullen THREE, which he identified as “the customers, piloting, testing and evaluation stage. Demand has been strong since we introduced this product and the aggressive price point. We are excited to get customers behind the wheel of our class 3 product.”

In addition, Mullen signed a vehicle purchase agreement, valued at more than $15.7 million, with MGT Lease Company, for 250 class 3 cab chassis EV trucks. According to the agreement, Mullen will begin delivering the first of the trucks in August 2023, with all vehicles being delivered by the end of the year.

A growing commercial vehicle sales and leasing company based in North Carolina, MGT is focused on a customer base that is looking for last-mile delivery solutions, such as package delivery and retail, along with vocations such as plumbing and electrical. MGT has ordered the all-electric class 3 EV cab chassis trucks for addition to its short- and long-term fleet leasing portfolio. MGT has worked with Mullen before; the company initially purchased EV cargo vans earlier this year. “We are very happy with the Mullen EV cargo van and have received great customer feedback and are now looking forward to expanding into Mullen’s commercial class 3 truck,” said Greg Striker, a partner at MGT Lease Co.

Mullen Automotive (NASDAQ: MULN) is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

Gene Therapy’s Transformative Potential Highlighted in Inspiring Patient Video Interview with Genprex’s (NASDAQ: GNPX) REQORSA on Benzinga.

Click Here for the full article

The interview showcases the real-life experience of a patient participating in a clinical trial utilizing Genprex’s innovative gene therapy drug candidate, REQORSA, shedding light on the significant impact it could potentially have in advancing the treatment of non-small cell lung cancer.

The featured video highlights the compelling story of Jacqueline Marino, a participant in the Phase 1 segment of Genprex’s Phase 1/2 Acclaim-1 clinical trial. Marino, diagnosed with non-small cell lung cancer (“NSCLC”), offers an inspiring account of her experience with REQORSA(R) Immunogene Therapy, Genprex’s flagship drug candidate, in combination with Tagrisso(R).

Marino’s narrative centers on the significant positive impact REQORSA has had on her life. Her treating physician observed that her lung cancer lesions remained stable, devoid of any signs of growth. This stability, combined with an extended period of Progression-Free Survival (“PFS”), has led to an enhanced quality of life and invaluable additional time for Marino.

REQORSA Immunogene Therapy represents a potentially groundbreaking experimental drug that harnesses the power of genetic medicine to combat NSCLC. The Acclaim-1 trial evaluates the safety and efficacy of combining REQORSA with Tagrisso in patients with advanced EGFR mutant NSCLC who have experienced disease progression after previous treatments.

During the Phase 1 portion of the clinical trial, the primary emphasis is on evaluating the safety of the treatment. However, the findings also have revealed promising efficacy results. One patient previously treated with standard of care therapies such as osimertinib had a partial remission (“PR”) by investigator evaluation and treatment is ongoing after 16 cycles, which is approximately 10.5 months. Another patient previously treated with osimertinib, has stable disease and treatment is ongoing after 14 cycles, or approximately 9 months. The extended and ongoing progression free survival (“PFS”) of each of these patients is significantly greater than the median PFS observed from treatment with osimertinib alone in this treatment setting in several prior clinical trials and is consistent with long-term PFS seen in prior clinical trials of REQORSA. These findings underscore the potential of REQORSA in reshaping the landscape of non-small cell lung cancer.

The release of the patient video interview on Benzinga coincides with the successful completion of the Phase 1 portion of the Acclaim-1 clinical trial. The compelling patient story, combined with the Safety Review Committee’s approval to proceed with the Phase 2 expansion segment, signify significant milestones in the development of REQORSA Immunogene Therapy.

While REQORSA is currently in early-stage clinical studies and will require successful large scale studies prior to regulatory approval and commercial availability, the patient video interview on Benzinga provides a captivating glimpse into the transformative potential of gene therapy. Marino’s journey serves as an inspirational testament to the promise of REQORSA in addressing the critical needs of NSCLC patients.

To watch Jacqueline Marino’s powerful story and delve deeper into REQORSA Immunogene Therapy, visit the featured video on Benzinga.

*It is important to note that REQORSA is an investigational drug and has not received approval from the U.S. Food and Drug Administration or any other regulatory authority. The experiences shared in the video are unique to Jacqueline Marino and may not be representative of the outcomes experienced by other patients undergoing REQORSA treatment.

For more information, visit the company’s website at www.Genprex.com.

NOTE TO INVESTORS: The latest news and updates relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX

• In 2019, Quebec became the first Canadian province to mandate the inclusion of renewable natural gas (“RNG”) in natural gas distribution; other provinces have followed suit
• EverGen Infrastructure as a renewable energy leader in Canada, specializing in RNG with operations in B.C., Alberta, and Ontario
• EverGen has agreements with provincial governments and businesses to bat for organic feedstock and supply agreements with major Canadian utilities, including FortisBC, to include RNG in their pipelines

Renewable energy forms a cornerstone of environmental sustainability, with nations worldwide realizing the immense potential of harnessing naturally occurring energy sources. One such pivotal renewable source is biogas, produced by the anaerobic digestion of organic waste from landfills, agricultural waste, and wastewater from treatment facilities. Biogas is further processed into RNG (renewable natural gas), a carbon-negative product that is essentially indistinguishable from conventional natural gas collected from drilled wells. Canada is fast becoming a global leader in this arena, as is EverGen Infrastructure (TSX.V: EVGN) (OTCQX: EVGIF), capitalizing on its unique attributes and comprehensive sustainability strategies that outshine many of its international counterparts.

A key advantage of Canada’s biogas push compared to other countries is its vastness and diverse landscapes. In 2019, Quebec became the first province to mandate the inclusion of RNG in natural gas distribution. According to Canada Energy Regulator,18 new RNG projects built after 2021 will increase Canada’s RNG capacity from 7.2 petajoules (“PJ”) in 2021 to 17.1 PJ in 2025. With expansive agricultural lands and numerous livestock operations, the country possesses an abundant and continuous supply of raw materials needed for biogas production. Notably, agricultural waste, a primary input, is available in substantial quantities, thereby creating a mutually beneficial relationship between agriculture and renewable energy sectors.

Secondly, the Canadian government’s strong commitment to environmental sustainability plays a significant role. Their strategies towards achieving the United Nations’ Sustainable Development Goals are comprehensive, clear, and measurable. It includes generous incentives for renewable energy investments and stringent regulations against carbon-intensive operations. This robust policy framework makes Canada an attractive destination for green tech investments and an incubator for biogas technologies.

A considerable advantage Canada has is its technological leadership in renewable energy. EverGen stands out at the forefront of renewable energy R&D, innovating and investing in RNG projects across the country to play an important role in production, storage, and distribution of RNG efficiently.

The British Columbia-based company has partnerships with jurisdictions and businesses for feedstock and output supply agreements with some of the nation’s biggest utilities, including FortisBC. FortisBC is a pioneer itself as a significant contributor to the province’s emissions reduction targets. The utility has a goal to have about 75 percent of the gas in its system being RNG or low carbon by 2050. Approached 12,000 homes and business in British Columbia are already using RNG, part of which is produced by EverGen from local organic waste.

This dovetails with the CleanBC strategy pursuant to which British Columbia is committed to a minimum requirement of 15% renewable content in the natural gas stream by 2030.

EverGen has three operations in B.C. Its Fraser Valley Biogas is an anaerobic digestion facility that utilizes local agriculture and commercial food processing waste to generate RNG and renewable fertilizer. Liquid and solid digestate matter is a byproduct of RNG production and is used as fertilizer and in other applications. Pacific Coast Renewables is an organics facility processing blended feedstock from agricultural, municipal, and commercial organic waste. Sea to Sky Soils is also an operational organics processing facility, more specifically a compost facility (feedstock from municipal and agricultural waste) operated in partnership with Lil’wat First Nation.

EverGen also has a 67% ownership of GrowTEC, an operational RNG facility in Alberta, and a 50% ownership in Project Radius in Ontario, an ambitious operating farm-scale anaerobic digester converting biodegradable waste into biogas.

Canada’s communal consciousness regarding sustainability and clean energy consumption makes it an optimal testing ground for renewable energy solutions. The country boasts one of the highest levels of education globally, with its citizens exhibiting a deep understanding and respect for the environment. This cultural attitude encourages widespread adoption of sustainable practices, creating a market for renewable energy technologies like biogas.

This harmonious blend of natural resources, proactive government policies, technological leadership, and communal consciousness has placed Canada at the forefront of the global biogas revolution. When contrasted with other countries, many lack either the necessary resources or the institutional support. For instance, while countries like Nigeria and Venezuela have enormous untapped natural resources, they lag behind due to inadequate regulatory support and sociopolitical instabilities. Countries like Singapore and the Netherlands possess strong institutional support and public awareness, but face constraints due to their limited land area and resources.

Canada’s sustainability push, particularly its focus on biogas, represents a commendable model for other countries. Its extensive natural resources, coupled with strategic government policies, leading-edge research, and a strong cultural emphasis on sustainability, have positioned Canada as a global leader in this arena. Its success in biogas utilization underscores the importance of a cohesive and well-rounded approach to sustainable development, providing valuable lessons for countries striving to make their economies greener and more sustainable.

For more information about EverGen Infrastructure, “Canada’s RNG Infrastructure Platform,” visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

Pharma, biotech, medical device, healthcare, and regulatory professionals are gathering for the 4th Aligning Drug Safety Functions & REMS Summit, taking place on August 29-30, 2023, at The Inn at Penn in Philadelphia, PA.

Set to take place in the beautiful city of Philadelphia, the conference will delve into the latest insights and address the most critical challenges surrounding drug safety and REMS (Risk Evaluation & Mitigation Strategy).

As the only event that brings together drug safety, pharmacovigilance, and risk management teams—no other conference provides as much detail and comprehensive insights into communication strategies among safety teams, prioritizing patient safety, and preparing for pharmacovigilance and REMS inspections. Attendees will walk away armed to effectively up their game and amplify patient feedback and participation in REMS programs.

Interactive and Inspirational Discussions!

With a well-rounded agenda focused on the latest advances in drug safety and REMS space, the program is designed to provide attendees with all the tools they need to develop and implement a robust global risk management plan.

Featuring interactive discussions, such as exploring the critical intersection of REMS and pharmacovigilance in shared REMS systems, discovering the power of AI to optimize REMS implementation, strategies to improve signal management and detection, fortifying compliance and quality in post-approval studies. Delve into the cutting-edge realm of patient-centricity for benefit-risk assessment and their implications for the future of healthcare.

Throughout the two-day summit, attendees will be able to connect with an outstanding lineup of expert speakers and industry leaders and learn network, and interchange ideas and innovative approaches surrounding drug safety and REMS strategies to better support patient safety.

Sign up and forge a safer and more patient-centric future at the most trusted drug safety event. Interested participants can register for this summit and secure their tickets at early-bird prices.

To learn more, please visit https://ibn.fm/otdWA.

As the Internet becomes a worldwide driver of communication and culture, enthusiasts from diverse business and entertainment backgrounds continue working toward the Internet’s evolution into a content ownership, decentralized community known as Web3.

The leadership team behind the inaugural Web3 Berlin (“W3B”) conference is determined to see it become Europe’s largest gathering of innovators in the Web3 ecosystem with gatherings on an annual basis.

The two-day event will take place at Berlin’s Estrel Congress Center (“ECC”) on June 10-11, hosting hundreds of speakers and panelists, exhibitor spaces, networking opportunities and a variety of side events such as a gamer gathering, a hackathon competition, NFT-centered parties and crypto community strategy sessions.

The Web3 evolution is ultimately designed to unleash greater utility and self-determination for users of the Internet while bringing a more level financial and technological playing field to even remote populations around the world. It’s a progression of the Internet from the original read-only content sharing model to today’s read-write content sharing, to tomorrow’s read-write-own approach to information and commerce.

The W3B conference will logically include a focus on decentralized finance (Defi), crypto universe developments as markets continue to fluctuate with some uncertainty, and the investment culture opportunities that non-fungible tokens (“NFTs”) represent as the opportunity ecosystem continues to expand.

The conference’s engaging side event activities are designed to turn the gathering into a lifestyle experience reflective of Berlin’s multicultural and history-making persona. Gamers, venture capitalists, hackers and CEOs can all be found under one roof, working toward a somewhat singular purpose as seasoned industry insiders and newcomers alike.

A VIP ticket tier is available to make the event extra productive for those seeking opportunities to network in a space amenable to relaxation over food and drinks.

Key takeaways:

• Located at one of Europe’s primary multicultural hubs
• A speaker and panel profile of 300 CEOs, financial strategists and event builders
• Forums for focusing on NFT investment, crypto community building and the decentralized finance (Defi) vision of blockchain
• Side events include a hackathon competition for developers
• A gaming space for players to connect and view the latest developments
• More than 8,000 people expected to attend
• Specialized opportunities for networking

Behind the Scenes:

The team establishing the W3B conference’s B3B infrastructure includes an energetic and diverse group of employees and advisers focused on content creation and Web3 culture. Many of them hail from backgrounds in Poland’s international gateway economy, but reflect commercial and web marketing experience built throughout Europe and Asia.

For more information about this event, please visit https://ibn.fm/51rTg.

This summer, Canada’s largest crypto, web3, and blockchain event – Blockchain Futurist Conference – returns to Rebel Entertainment and Cabana Pool Bar in Toronto, assembling more than 6,500 attendees and over 150 speakers. The unconventional venue will provide the perfect setting for a two-day one-of-a-kind crypto experience slated for August 15-16, 2023. The event will feature three stages, two floors of expo booths, crypto marketplaces, NFT galleries, blockchain bootcamps for beginners, networking events, and two developer hackathons: ETHToronto and ETHWomen.

The Main Stage will host a curated list of top speakers who will deliver presentations and industry keynotes on the future of emerging technologies and how they impact the social, economic, political, and environmental landscape of the global economy. Here, the speakers will also provide insights into industries that are being disrupted or transformed. This stage will also form the perfect setting for speakers and presenting companies to make major announcements, launch products on-stage, and showcase innovative solutions for the first time.

Three stages include panel discussions, where speakers debate technologies such as NFTs (non-fungible tokens), DAOs (Decentralized Autonomous Organizations), GameFi, the metaverse and more. The Purple Stage is geared specifically towards bootcamps and workshops, enabling beginners to learn about blockchain and allied technologies.

One consistent fact that emerges from all Blockchain Futurist Conferences is that they promise a glimpse into topics even before they become mainstream. This is thanks, in part, to the selection committee, which carefully curates the top speakers and sends specific invites for mainstage slots. This has often resulted in stellar coverage of emerging technologies. For example, during past events, attendees heard about the future of decentralized finance, NFTs, the metaverse, and artificial intelligence even before they became buzzwords. The upcoming fifth edition will be no different.

The 5th Annual Blockchain Futurist Conference will bring together world-class speakers, including:

• Charles Hoskinson, CEO and Founder of IO Global, best known for the cryptocurrency Cardano, and Tamara Haasen, President of IO Global; which is a technology and engineering company that builds blockchains and cryptocurrencies for government entities, enterprises, and academic institutions
• Michele Romanow, a resident “Dragon”, on CBC Dragons’ Den and Co-Founder and Executive Chairperson of Clearco, a company that provides equity-free capital solutions to e-commerce businesses
• Anthony Di Iorio, Founder of Andiami, Decentral, and Ethereum
• Jaime Leverton, CEO of Hut 8, an innovation-focused digital asset miner
• Ethan Buchman, Co-Founder of Cosmos, a state-of-the-art blockchain framework 
• Miko Matsumara, General Partner at gumi Cryptos Capital, a blockchain and cryptographic asset fund
• Lisa Loud, Co-Founder and CEO of FLUIEFI, a DEFI company for institutional investors
• Sascha Darius Mojtahedi, Co-Founder of Parallel, a DeFi company

Beyond the speakers, the ETHToronto and ETHWomen Hackathons will take over a month leading up to Blockchain Futurist Conference. The hackathons workshops, mentorship, mock judging and networking will take place onsite on August 15-16 at Rebel Entertainment Complex and Cabana.  This second annual Web3 hackathon, ETHToronto, is a free community event (https://ibn.fm/IqzqF). The first ever ETHWomen Hackathon is a female-focused, inclusive hackathon series that is part of the ETHToronto and Blockchain Futurist Conference (https://ibn.fm/mu6lp). Apply for free to any of the hackathons and receive free tickets to the conference.

By combining carefully curated presentations and discussions, NFT galleries, boot camps and workshops, expo booths, and networking events into a well-thought-out two-day event, Untraceable Events, the organizers of the 5th annual Blockchain Futurist Conference, ETHToronto, ETHWomen and Canada Crypto Week will indeed promise a crypto experience like no other.

To learn more, visit https://ibn.fm/mdYRG.

• Starco Brands launches Lime Whipshots(TM) flavor in collaboration with Cardi B., kickstarts “Whip It, Beaches” campaign with teaser post earning nearly 2 million likes in one day
• Whipshots Lime is available now in-store and online on June 14
• “Whip It, Beaches” features a 30-second video and series of images showcasing the product’s use in a variety of summer cocktails
• Whipshots is infused with 10% premium vodka, other flavors include vanilla, caramel, and mocha
• Over 2 million cans of Whipshots have been sold since 2021 launch
• Other Starco Brands offerings include the Art of Sport athletic body care line co-founded by Kobe Bryant, Skylar hypoallergenic perfumes, Winona popcorn spray, Soylent plant-based food product line

Starco Brands’ (OTCQB: STCB) “Summer of Whipshots(TM)” kicked into high gear with the launch of Lime Whipshots – the company’s latest addition to its vodka-infused whipped cream product line featuring global icon Cardi B (https://ibn.fm/BOJRg). Currently available in retail stores, Lime Whipshots is scheduled to drop online on June 14 as part of the brand’s “Whip It, Beaches” campaign.

“Whip It, Beaches” features Cardi B. in a 30-second video and series of images showcasing the product’s use in various summer drinks, including mojitos, margaritas, and daiquiris. The campaign is already generating significant buzz among Cardi’s 164 million followers, with nearly 2 million likes on the product’s initial pre-launch post (https://ibn.fm/NEqr8).

“We are thrilled to dive headfirst into the ‘Summer of Whipshots’ with Lime as the latest flavor in our Whipshots family,” says Ross Sklar, CEO of Starco Brands (https://ibn.fm/eHLtC). “Having recently surpassed two million cans sold, Whipshots continues to offer consumers a fun and innovative way to celebrate all year.”

Whipshots Lime joins other flavors in the product line, including vanilla, caramel, and mocha – all infused with a premium 10% premium vodka kick. Starco Brands launched the product in 2021 in collaboration with the Republic National Distributing Company and has since sold millions of cans to make it one of the “largest consumer product launches of the year”, according to the company (https://ibn.fm/mwNzM). Whipshots has also gained widespread industry recognition with several awards, including the “Rising Star” award at the Beverage Dynamics’ 2023 Growth Brands Awards and four medals at the 2023 DB&SB Spring Blind Tasting segment of the Global Spirits Masters Competition (https://ibn.fm/0qs52).

Starco Brands is a modern-day “invention factory” that invents or acquires novel products and advances them using behavior-changing technologies. The company’s revenues grew from approximately $2 million to a current run rate of approximately $67 million in annual revenue in one year through a powerful end-to-end strategy that first identifies game-changing products in eight core consumer spaces, and then disrupts the market with the power of globally recognized celebrities and influencers.

Other Starco Brands offerings include Art of Sport, a line of premium body and skincare products co-founded by Kobe Bryant and engineered to power and protect athletes; Skylar, a prestige line of hypoallergenic fragrances distributed through Sephora and Nordstrom and a large DTC subscription business; Winona, first indulgent theater-popcorn spray powered by air; and Soylent, known as the “world’s most perfect food.”

For more information, visit the company’s website at www.StarcoBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to STCB are available in the company’s newsroom at https://ibn.fm/STCB

• The world’s top polluters are on a mission to limit climate change to “well below” 2 degrees C, but time is moving quickly to meet goals over the next three decades
• GeoSolar Technologies offers a comprehensive, integrated package that heats, cools, and powers a home with 100% renewable energy
• A SmartGreen(TM) home includes rooftop solar system, geothermal heating and cooling technology, CERV air filtration, upgraded insulation, electric heat pump, EV charging station, and more

The goal is clear: limit global warming to 1.5 degrees Celsius (2.7 degrees F). According to Climate Watch’s Net Zero Tracker, 91 countries, representing 95 countries and 78.9% of global greenhouse gas (“GHG”) emissions, have communicated a net-zero target, including 71 either via law or document. As detailed in a recent report by the Natural Resources Defense Council (“NRDC”), the most impactful path to meeting net-zero targets by 2050 is through carbon-free electricity in combination with energy efficiency upgrades. As the window narrows to reach emissions goals, companies like the Colorado-based GeoSolar Technologies (“GST”) are providing comprehensive, cost-effective solutions, while setting the benchmark for a building’s efficiency.

There is a growing choir of voices regarding the sense of urgency that has emerged. IPCC (Intergovernmental Panel on Climate Change) warns that GHG emissions will need to be cut essentially in half by 2030 to reach net zero by 2050. “Net zero” has become a mainstream phrase simply meaning that any emissions from human activities are offset by removing carbon from the atmosphere. The shortest pathway is by eliminating emissions created from fossil fuels (mostly used for energy, albeit cars, factories, homes, etc.).

Reaching net zero by 2050 is not only about reducing emissions but also about enhancing carbon sinks. Restoring and conserving forests, promoting sustainable agriculture, and investing in carbon capture and storage technologies can significantly boost our carbon absorption capacity. These actions, too, need time to show their effect, underscoring the urgency of starting now.

The World Meteorological Organization says that the world has warmed 1.2 degrees C since before the industrial revolution in the late 1800s. The Paris climate accord has the goal of reducing warming by “well below” 2 degrees C, ideally to 1.5 degrees C. Exceeding a rise of 1.5 degrees C has scientists concerned that heatwaves and droughts will become more severe, nearly all coral reefs could die, sea level will rise 10-30 inches, and transitions in biomes will occur, such as grasslands turning to desert and tundra becoming forest.

Understand that not reaching net zero doesn’t mean that all these things happen at the stroke of midnight January 1, 2050. The target is set based upon current science, which points to the idea that further after 2050 the target is met, the greater the odds of exceeding a rise of 1.5 degrees C becomes. As 2060 approaches, it will be a near certainty and require even greater efforts to bring the planet back into the safer limit. Simply put, every delay in reducing emissions increases the pace and magnitude of the changes required later.

GeoSolar Technologies has developed a solution, dubbed the “SmartGreen(TM) Home system,”  that is applicable to tens of millions of homes in the U.S. alone to eliminate their need to use fossil fuels. SmartGreen(TM) homes utilize the power of the sun, ground, and modern technology to makes homes that are heated, cooled, and powered with 100% natural energy sources and capable of operating off-grid.

The patent-pending integrated system spans roof-to-underground. It begins with a thorough home analysis and upgraded insulation as required. From there, a roof-top photovoltaic (“PV”) solar system is sized and installed to provide all the electricity for the home. Gas appliances can be replaced with high-efficiency electric. Fossil-fuel heating and cool systems are exchanged with high-efficiency heat pumps, which include geothermal ground loops. Leveraging science behind the ground temperatures remaining warmer than the air in the winter and cooler in summer, air is forced through piping that changes its temperature, which is subsequently used to heat or cool the home.

To that point, integrated floor loops and air ducts provide heating, cooling, and hot water year round for a SmartGreen(TM) home. CERV(R) Air Filtration is built into the system for healthy and safe indoor air quality that prevents COVID-19 and other pollutants. Charging stations are also part of the package for those with (or wanting) an electric vehicle.

GST even makes sure its customers are reaping every possible financial incentive and benefit to transition to carbon-free energy and also helps secure financing.

A SmartGreen(TM) home is the embodiment of NRDC’s advice as to the fastest path to net zero and the data supports it. GST home technology has been installed in multiple test homes in Colorado with exceptional results, including some of the most impressive energy efficiency ratings in the industry as measured by HERS, the gold standard in validating home efficiency.

Action now allows for the harnessing of the economic opportunities inherent in the transition to a net zero economy. Renewable energy, green infrastructure, and sustainable technology can become engines of growth, generating millions of jobs, and driving innovation. But to seize these opportunities, we must create an enabling environment today. Investments made now will yield returns over decades, fostering a more resilient and sustainable economy.

For more information, visit the company’s website at www.GeoSolarPlus.com.

NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• Lexaria just announced the completion of batch manufacturing of its patented DehydraTECH(TM)-processed CBD and placebo materials for its FDA Phase 1b HYPER-H23-1 human clinical study
• This is in line with the company’s IND filing with the FDA, which it looks to complete this summer, with potential authorization within 60 days
• FDA authorization will mark the commencement of Phase 1b trial patient dosing, with the study evaluating the safety and tolerability of DehydraTECH-CBD in hypertensive patients
• Filling into capsules of the manufactured DehydraTECH-CBD is expected to be completed before the end of this month, after which analytical release and stability testing will be conducted

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, announced an ambitious plan to embark on its Food and Drug Administration (“FDA”)-registered, U.S. Phase 1b Investigational New Drug (“IND”) hypertension study, HYER-H23-1. Earlier in May, the company announced the awarding of the contract for clinical research organization (“CRO”) services to California-based InClin, Inc. Since this announcement, it has completed batch manufacturing of its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) and placebo materials for the study (https://ibn.fm/cb444).

Lexaria retained the services of a U.S. contract manufacturing organization to produce these study materials, in line with current Good Manufacturing Practice (“cGMP”) regulations as directed by the FDA. With everything on track, the company looks to file the IND this summer, with potential authorization by the FDA within 60 days in what will mark the commencement of Phase 1b trial patient dosing, possibly in October 2023.

Titled “A Phase 1b Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of DehydraTECH-CBD in Subjects with Stage 1 or Stage 2 Hypertension,” Hyper-H23-1 will explore the safety and tolerability of its DehydraTECH-CBD in hypertensive patients. It will also monitor the efficacy evaluation in reducing blood pressure together with detailed pharmacokinetic testing, building on the five previous human clinical studies which evidenced significant reductions in resting blood pressure over both acute and multi-week dosing regimens with zero serious adverse events.

The filling into capsules of the manufactured DehydraTECH-CBD is expected to be completed before the end of this month, after which analytical release and stability testing will be conducted to gather essential quality control data essential for the IND filing. So far, DehydraTECH-CBD has shown the potential to have pronounced clinical benefits relative to available anti-hypertensive therapeutics. In addition, none of the other published studies thus far have shown a sustained decrease in resting blood pressure following multiple weeks of oral CBD dosing, demonstrating DehydraTECH-CBD’s superior power to reduce blood pressure over other oral CBD formulations.

Finalized DehydraTECH-CBD batch manufacturing marks a significant step towards IND filing and subsequent FDA approval for Lexaria. It also marks a notable achievement for the company, especially given the multiple human clinical studies conducted since 2018 and the over 130 healthy and hypertensive persons that have taken part in the studies so far. Its management is optimistic about the HYPER-H23-1 clinical study and is confident that results from the company’s previous efforts will be replicated, if not exceeded.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price
• Data from pre-clinical trial indicate that BiondVax’s NanoAb may effectively serve as both a therapeutic and protective prophylactic drug, further enhancing its value proposition
• BVXV reiterated further NanoAb development beginning with NanoAbs targeting immune system cytokines such as IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
• BiondVax aims to optimize the use of assets and generate additional revenues by offering its drug development services and cGMP manufacturing capabilities to others

BiondVax Pharmaceuticals (NASDAQ: BVXV), an innovative biotechnology company developing unique NanoAb immunotherapeutic products for the treatment of infectious disease and large market autoimmune disorders, recently published the financial results for the three months ended March 31, 2023 – Q1 2023 – and provided a business update (https://ibn.fm/GBZmz).

The Q1 2023 results were in line with analysts’ expectations. R&D expenses increased about $800k from Q1 2022 which BiondVax attributed to the initiation and ramp-up of R&D activities for its innovative nanosized VHH antibody (“NanoAb”) platform. In particular, the company finalized a preclinical proof-of-concept study of its inhaled anti-COVID NanoAb drug, reporting in January that the therapy virtually eliminated the SARS-CoV-2 virus in the lungs of infected hamsters (https://ibn.fm/jbZbP) and virtually prevented illness when inhaled prophylactically (https://ibn.fm/F8lWc). These results built on previously announced data indicating the NanoAb treatment led to significantly milder illness and faster recovery among hamsters in the experimental group compared with the control group (https://ibn.fm/ednie).

Bullish about BiondVax, the analysts at Aegis Capital Corp. continue to recommend shares of the company with a Buy rating and a $70 target price. The analysts noted that the “Results were generally in-line with our expectations.” The analysts specifically highlighted R&D expenses of $5.8 million, which were in line with expectations, BVXV has announced intent for further NanoAb development starting with NanoAbs targeting large market immune system disorders such as psoriasis and psoriatic arthritis.

The company’s R&D efforts are the product of several exclusive and definitive agreements BiondVax entered with the Max Planck Society (“MPG”) and the University Medical Center Göttingen (“UMG”), both in Germany. In 2021, for instance, BiondVax signed its first set of agreements, announcing entry into a strategic collaboration and exclusive worldwide license for the development and commercialization of innovative COVID-19 NanoAbs (https://ibn.fm/uPGQq).

These agreements were part of a broader partnership that was crystallized in a definitive collaboration agreement announced last year for the development of NanoAbs addressing diseases with significant unmet medical needs and attractive commercial opportunities, such as asthma, psoriasis, psoriatic arthritis, and macular degeneration. The collaboration agreement also gave BiondVax an exclusive option for an exclusive worldwide license for further development and commercialization of resultant therapies (https://ibn.fm/VBf9M).

“BiondVax’s recent achievements leave me very optimistic about BiondVax’s growth potential and ability to deliver value to our stakeholders,” said BiondVax CEO Amir Reichman in the press release announcing FY 2022 results. “Looking forward, I’m excited to exercise our option to obtain an exclusive license at pre-agreed financial terms to anti-IL-17 NanoAbs targeting safe, effective, and convenient treatment of psoriatic lesions; scale up in-house NanoAb manufacturing; and conduct an in vitro proof-of-concept study and potentially also a preclinical trial of the IL-17 NanoAb as a therapy for psoriasis.”

And as BiondVax continues to prioritize its NanoAb pipeline development in line with its core focus, it has also sought to optimize the use of its assets and generate revenues. For example, the company stated in its business update that it is offering its cGMP manufacturing capabilities to interested parties, including an aseptic fill and finish suite, state-of-the-art technical R&D and quality control laboratories, and experienced professionals for CDMO (Contract Development and Manufacturing Organization) services. According to the company’s website (https://ibn.fm/A0uce), its assets for potential clients’ CDMO needs include the following:

• cGMP-ready production clean rooms
• Aseptic fill and finish for clinical trials and pilot-scale manufacturing
• Ambr(R) 250, 2L, and 5L fermenters for upstream process development and optimization
• 30L and 300L fermentors for upstream GMP production
• Downstream GMP production: Akta Process, BPG columns, single-use mixers
• Analytic tools
• Water for injection (“WFI”)
• Media and buffer preparations, with equipment such as 50L to 1500L single-use mixers, 200L and 500L storage containers, a power transfer system, and a suction arms system

BiondVax boasts unique big pharma competencies, positioning it to bring innovative therapies to market quicker and at lower cost compared to other companies of similar size. With a $70 price target and currently trading under $2 per share, those that understand risk reward ratios should keep BVXV on their radar.

For more information, visit the company’s website at www.BiondVax.com.

NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV